Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 5/20 | 0.36 |
| ▸ | BRD4 | O60885 | 4/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.35 |
| ▸ | HAT1 | O14929 | 4/20 | 0.35 |
| ▸ | EP300 | Q09472 | 4/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | CLK2 | P49760 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21946619 | 0.88 | BRD4 (0.42) | CREBBPBRD4GRM2USP30BTK | |
| SCHEMBL21946618 | 0.84 | PLAT (0.39) | AAK1CREBBPBRD4GRM2USP30 | |
| SCHEMBL19128840 | 0.84 | SPR (0.45) | AAK1CREBBPBRD4USP30 | |
| SCHEMBL17452657 | 0.80 | KEAP1 (0.38) | CREBBP | |
| SCHEMBL20646831 | 0.75 | ROCK2 (0.39) | — | |
| SCHEMBL17452701 | 0.74 | HAT1 (0.54) | BRD4USP30HAT1EP300 | |
| SCHEMBL20646785 | 0.72 | ROCK2 (0.37) | — | |
| SCHEMBL20647176 | 0.72 | ROCK2 (0.38) | — | |
| SCHEMBL17452627 | 0.71 | ROCK2 (0.52) | — | |
| SCHEMBL20646931 | 0.70 | ROCK2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10611776-B2 | Spiroheptane salicylamides and related compounds as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190016735-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2019-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016735-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | ROCK1, MYLK, RHOA | AAK1 775/4885CREBBP 1378/4885BRD4 2778/4885 |
| US-10611776-B2 | Spiroheptane salicylamides and related compounds as inhibitors of rock | ROCK1, MYLK, RHOA | AAK1 775/4885CREBBP 1378/4885BRD4 2778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.